Insulin-like Growth Factor Binding Protein-1 and Insulin in Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jan 4

PMID 38174331

Authors

Yuxin Jin

Fei Sun

Aili Yang

Xinwen Yu

Yi Li

Shengru Liang

Xiaorui Jing

Kai Wang

Lan Zhang

Sa Xiao

Wencheng Zhang

Xiaoguang Wang

Guohong Zhao

Bin Gao

Affiliations

Soon will be listed here.

Abstract

Background: Insulin-like growth factor binding protein-1 (IGFBP-1) is considered a decline in polycystic ovary syndrome (PCOS), but it remains controversial that whether such reduction is attributed to obesity.

Aims: This systematic review aims to explore whether IGFBP-1 is reduced in PCOS, and whether such reduction is associated with obesity.

Results: Our pooled study included 12 studies with a total of 450 participants. IGFBP-1 levels in PCOS were significantly lower than that in non-PCOS (SMD (95%CI)=-0.49(-0.89, -0.09), =0.02). No significant difference in IGFBP-1 levels between patients with or without PCOS classified by BMI. Whilst, stratification by PCOS status revealed a significant decrease in IGFBP-1 in overweight (SMD (95%CI)=-0.92(-1.46, -0.37), P=0.001). When comparing fasting insulin in the same way, PCOS patients had significantly elevated fasting insulin level but not statistically declined IGFBP-1 after classified by BMI.

Conclusion: This meta-analysis provides evidence that the decrease of IGFBP-1 in PCOS was more strongly influenced by comorbid obesity than by PCOS itself. Additionally, contrast to previous findings that insulin significantly suppresses IGFBP-1, our results suggested that the suppression of PCOS-related hyperinsulinemia on IGFBP-1 seemed diminished. Overall, our work may provide a novel perspective on the mechanism between insulin and IGFBP-1 underlying PCOS development.

Citing Articles

Gonadal miRNomes and transcriptomes in infected fish reveal sexually dimorphic patterns of the immune response.

van Gelderen T, Debnath P, Joly S, Bertomeu E, Duncan N, Furones D Funct Integr Genomics. 2025; 25(1):29.

PMID: 39883212 PMC: 11782434. DOI: 10.1007/s10142-025-01537-w.

The impact of inactivation of the GH/IGF axis during aging on healthspan.

Poudel S, Ruff R, He Z, Dixit M, Yildirim G, Jayarathne H Geroscience. 2024; .

PMID: 39535693 DOI: 10.1007/s11357-024-01426-3.

Association between Coffee Consumption and Polycystic Ovary Syndrome: An Exploratory Case-Control Study.

Meliani-Rodriguez A, Cutillas-Tolin A, Mendiola J, Sanchez-Ferrer M, De la Cruz-Sanchez E, Vioque J Nutrients. 2024; 16(14).

PMID: 39064680 PMC: 11279816. DOI: 10.3390/nu16142238.

References

Hernandez-Jimenez J, Barrera D, Espinoza-Simon E, Gonzalez J, Ortiz-Hernandez R, Escobar L . Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. Gynecol Endocrinol. 2021; 38(1):2-9. DOI: 10.1080/09513590.2021.2003326. View

Iwashita M, Mimuro T, Watanabe M, Setoyama T, Matsuo A, Adachi T . Plasma levels of insulin-like growth factor-I and its binding protein in polycystic ovary syndrome. Horm Res. 1990; 33 Suppl 2:21-6. DOI: 10.1159/000181561. View

Escobar-Morreale H . Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018; 14(5):270-284. DOI: 10.1038/nrendo.2018.24. View

Liu B, Cai L, Lv H, Xia L, Zhang Y, Zhang H . Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. Gynecol Endocrinol. 2008; 24(5):285-8. DOI: 10.1080/09513590802056995. View

Garcia-Rudaz M, Ropelato M, Escobar M, Veldhuis J, Barontini M . Amplified and orderly growth hormone secretion characterizes lean adolescents with polycystic ovary syndrome. Eur J Endocrinol. 2002; 147(2):207-16. DOI: 10.1530/eje.0.1470207. View

Mounier C, Posner B . Transcriptional regulation by insulin: from the receptor to the gene. Can J Physiol Pharmacol. 2006; 84(7):713-24. DOI: 10.1139/y05-152. View

Chiofalo B, Lagana A, Palmara V, Granese R, Corrado G, Mancini E . Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype?. Med Hypotheses. 2017; 105:1-3. DOI: 10.1016/j.mehy.2017.06.013. View

Kowalska I, Kinalski M, Straczkowski M, Wolczyski S, Kinalska I . Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2001; 144(5):509-15. DOI: 10.1530/eje.0.1440509. View

Goyal M, Dawood A . Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review. J Hum Reprod Sci. 2017; 10(3):154-161. PMC: 5672719. DOI: 10.4103/jhrs.JHRS_77_17. View

10.

Tiitinen A, Laatikainen T, Seppala M . Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease. Fertil Steril. 1993; 60(1):58-62. DOI: 10.1016/s0015-0282(16)56036-1. View

11.

Tomkin G, Owens D . Obesity diabetes and the role of bile acids in metabolism. J Transl Int Med. 2017; 4(2):73-80. PMC: 5290900. DOI: 10.1515/jtim-2016-0018. View

12.

Borai A, Livingstone C, Heald A, Oyindamola Y, Ferns G . Delta insulin-like growth factor binding protein-1 (ΔIGFBP-1): a marker of hepatic insulin resistance?. Ann Clin Biochem. 2013; 51(Pt 2):269-76. DOI: 10.1177/0004563213495818. View

13.

Bhangoo A, Gupta R, Shelov S, Carey D, Accacha S, Fennoy I . Fasting Serum IGFBP-1 as a Marker of Insulin Resistance in Diverse School Age Groups. Front Endocrinol (Lausanne). 2022; 13:840361. PMC: 9108162. DOI: 10.3389/fendo.2022.840361. View

14.

Kelly C, Stenton S, Lashen H . Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2010; 17(1):4-16. DOI: 10.1093/humupd/dmq027. View

15.

Yuan F, Zhang Q, Dong H, Xiang X, Zhang W, Zhang Y . Effects of Des-acyl Ghrelin on Insulin Sensitivity and Macrophage Polarization in Adipose Tissue. J Transl Int Med. 2021; 9(2):84-97. PMC: 8386331. DOI: 10.2478/jtim-2021-0025. View

16.

Piltonen T . Polycystic ovary syndrome: Endometrial markers. Best Pract Res Clin Obstet Gynaecol. 2016; 37:66-79. DOI: 10.1016/j.bpobgyn.2016.03.008. View

17.

Shah J, Sabouni R, Cayton Vaught K, Owen C, Albertini D, Segars J . Biomechanics and mechanical signaling in the ovary: a systematic review. J Assist Reprod Genet. 2018; 35(7):1135-1148. PMC: 6063820. DOI: 10.1007/s10815-018-1180-y. View

18.

Nybacka A, Carlstrom K, Stahle A, Nyren S, Hellstrom P, Linden Hirschberg A . Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertil Steril. 2011; 96(6):1508-13. DOI: 10.1016/j.fertnstert.2011.09.006. View

19.

Lin Y, Weng X, Huang B, Guo H, Xu Y, Peng Y . IGFBP-1 in cancer: expression, molecular mechanisms, and potential clinical implications. Am J Transl Res. 2021; 13(3):813-832. PMC: 8014352. View

20.

Morris D, Falcone T . The relationship between insulin sensitivity and insulin-like growth factor-binding protein-1. Gynecol Endocrinol. 1996; 10(6):407-12. DOI: 10.3109/09513599609023605. View